Key Details
Price
$2.40Annual ROE
-12.53%Beta
1.94Events Calendar
Next earnings date:
Feb 28, 2025Recent quarterly earnings:
Nov 6, 2024Recent annual earnings:
Feb 29, 2024Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
N/AAnalyst ratings
Recent major analysts updates
Jan 23, 25 HC Wainwright & Co.
BuyJan 22, 25 HC Wainwright & Co.
BuyJan 7, 25 RBC Capital
OutperformJan 6, 25 HC Wainwright & Co.
BuyNov 7, 24 RBC Capital
OutperformOct 22, 24 Wedbush
OutperformSep 16, 24 HC Wainwright & Co.
BuySep 11, 24 Wedbush
OutperformAug 6, 24 RBC Capital
OutperformJul 17, 24 HC Wainwright & Co.
BuyMarket Data
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Price
Market cap
Technical
Dividend
Nuvation Bio doesn't have historical dividend data
Profitability
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Revenue
Profit
EPS
ROA & ROE
EBIT & EBITDA
Valuation
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
PE Ratio
PB Ratio
PS Ratio
Enterprise value
EV/EBITDA
Financial Health
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Liquidity
Leverage
Risk & Stability
Balance Sheet
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Assets
Equity
Liabilities
Debt
Expenses
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Cash Flow
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Cashflow Activities
Free CashFlow
CAPEX
Institutional Ownership
Positive Pooled Data from Nuvation Bio's TRUST-I and TRUST-II Studies Highlight Taletrectinib's Best-in-Class Potential for Patients with Advanced ROS1-positive NSCLC, Supporting Planned New Drug Application Submission in the Fourth Quarter of 2024
NUVB
businesswire.comSeptember 14, 2024
NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a late clinical-stage, global biopharmaceutical company tackling some of the greatest unmet needs in oncology, today announced positive pooled data from the pivotal Phase 2 TRUST-I and TRUST-II studies evaluating taletrectinib, an investigational next-generation ROS1 TKI. The findings will be highlighted in a poster presentation on September 14, 2024, at the European Society of Medical Oncology (ESMO) Congress 2024 in Barcelona, Spain.
Nuvation Bio Inc. (NUVB) Is Up 25.28% in One Week: What You Should Know
NUVB
Zacks Investment ResearchMarch 8, 2024
Does Nuvation Bio Inc. (NUVB) have what it takes to be a top stock pick for momentum investors? Let's find out.
FAQ
- What is the ticker symbol for Nuvation Bio?
- Does Nuvation Bio pay dividends?
- What sector is Nuvation Bio in?
- What industry is Nuvation Bio in?
- What country is Nuvation Bio based in?
- When did Nuvation Bio go public?
- Is Nuvation Bio in the S&P 500?
- Is Nuvation Bio in the NASDAQ 100?
- Is Nuvation Bio in the Dow Jones?
- When was Nuvation Bio's last earnings report?
- When does Nuvation Bio report earnings?
- Should I buy Nuvation Bio stock now?
What is the ticker symbol for Nuvation Bio?
The ticker symbol for Nuvation Bio is NYSE:NUVB
Does Nuvation Bio pay dividends?
No, Nuvation Bio does not pay dividends
What sector is Nuvation Bio in?
Nuvation Bio is in the Healthcare sector
What industry is Nuvation Bio in?
Nuvation Bio is in the Biotechnology industry
What country is Nuvation Bio based in?
Nuvation Bio is headquartered in United States
When did Nuvation Bio go public?
Nuvation Bio's initial public offering (IPO) was on August 26, 2020
Is Nuvation Bio in the S&P 500?
No, Nuvation Bio is not included in the S&P 500 index
Is Nuvation Bio in the NASDAQ 100?
No, Nuvation Bio is not included in the NASDAQ 100 index
Is Nuvation Bio in the Dow Jones?
No, Nuvation Bio is not included in the Dow Jones index
When was Nuvation Bio's last earnings report?
Nuvation Bio's most recent earnings report was on Nov 6, 2024
When does Nuvation Bio report earnings?
The next expected earnings date for Nuvation Bio is Feb 28, 2025
Should I buy Nuvation Bio stock now?
As of today, analysts generally recommend a 'Strong buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions